MSD’s Acquisition of Themis Bioscience


Wolf Theiss and Covington & Burling advised MSD on the deal, while Brandl & Talos and Wilson Sonsini Goodrich & Rosati advised the selling shareholders, and McDermott Will & Emery and Herbst Kinsky advised Themis Bioscience.

As reported in CEE Legal Mater and in others online publications MSD completed the acquisition of 100% of Austrian biotech company Themis Bioscience.

MSD offers medicines, vaccines, biological therapeutics, consumer health products and products for animal health.

Themis Bioscience GmbH develops vaccines for the prevention of infectious diseases using proprietary vaccine platform technology. The shareholders of Themis Bioscience include Farallon Capital Management, Global Health Investment Fund, Adjuvent Capital, Wellington Partners Life Sciences, Ventech, Omnes-Fonds, Hadean Ventures, and Aws Gruenderfonds.

The Wolf Theiss team consisted of Partners Hartwig Kienast (Picture), Kurt Retter, Georg Kresbach, Ralf Peschek, Karl Binder, Consultant Adolf Zemann, Counsel Jochen Anweiler, Senior Associates Michael Kienzl, Paulina Pomorski, Associates Lukas Slameczka, Clemens Pretscher, Dominik Engel, Lisa Babler and Michael Meindl.

Covington & Burling’s team included Partners Catherine Dargan and Michael Riella.

The Brandl & Talos team included Partner Roman Rericha, Attorney Markus Arzt, Associates Stephan Strass and Matea Plavotic.

Wilson Sonsini’s team included Partners Robert Ishii and Miranda Biven.

The McDermott Will & Emery team was led by Partners Emmanuelle Trombe and David Lipkin.

Herbst Kinsky’s team included Partner Florian Steinhart and Attorney Felix Kernbichler.

Involved fees earner: Markus Arzt – Brandl & Talos; Matea Plavotic – Brandl & Talos; Roman Rericha – Brandl & Talos; Stephan Strass – Brandl & Talos; Catherine Dargan – Covington & Burling; Michael Riella – Covington & Burling; Felix Kernbichler – Herbst Kinsky; Florian Steinhart – Herbst Kinsky; David Lipkin – McDermott Will & Emery; Emmanuelle Trombe – McDermott Will & Emery; Miranda Biven – Wilson Sonsini Goodrich & Rosati; Robert Ishii – Wilson Sonsini Goodrich & Rosati; Jochen Anweiler – Wolf Theiss; Lisa Babler – Wolf Theiss; Karl Binder – Wolf Theiss; Dominik Engel – Wolf Theiss; Hartwig Kienast – Wolf Theiss; Michael Kienzl – Wolf Theiss; Georg Kresbach – Wolf Theiss; Michael Meindl – Wolf Theiss; Ralf Peschek – Wolf Theiss; Paulina Pomorski – Wolf Theiss; Clemens Pretscher – Wolf Theiss; Kurt Retter – Wolf Theiss; Lukas Slameczka – Wolf Theiss; Adolf Zemann – Wolf Theiss;

Law Firms: Brandl & Talos; Covington & Burling; Herbst Kinsky; McDermott Will & Emery; Wilson Sonsini Goodrich & Rosati; Wolf Theiss;

Clients: Adjuvant Capital; Aws Gruenderfonds; Farallon Capital Management, LLC; Global Health Investment Fund; Hadean Ventures; Merck Sharp & Dohme Corp.; Omnes Capital; Themis Bioscience; Ventech; Wellington Partners;